<SEC-DOCUMENT>0001171843-25-006022.txt : 20250923
<SEC-HEADER>0001171843-25-006022.hdr.sgml : 20250923
<ACCEPTANCE-DATETIME>20250923060906
ACCESSION NUMBER:		0001171843-25-006022
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20250923
FILED AS OF DATE:		20250923
DATE AS OF CHANGE:		20250923

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Addex Therapeutics Ltd.
		CENTRAL INDEX KEY:			0001574232
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			V8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39179
		FILM NUMBER:		251331662

	BUSINESS ADDRESS:	
		STREET 1:		CHEMIN DES MINES 9
		CITY:			GENEVA
		STATE:			V8
		ZIP:			CH-1202
		BUSINESS PHONE:		01141228841555

	MAIL ADDRESS:	
		STREET 1:		CHEMIN DES MINES 9
		CITY:			GENEVA
		STATE:			V8
		ZIP:			CH-1202
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>f6k_092325.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<html><head><title></title></head><body style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><div align="center"><div style="margin-top: 3pt; margin-bottom: 12pt;"><div style="font-size: 1pt; border-top: Black 2.5pt solid; border-bottom: Black 1.1pt solid; width: 100%;">&#160;</div></div><p style="font-size: 14pt;" align="center"><strong>UNITED STATES</strong><br /><strong>SECURITIES AND EXCHANGE COMMISSION</strong><br /><strong>Washington, D.C. 20549</strong></p><p style="font-size: 14pt; text-transform: uppercase;" align="center"><strong>Form 6-K</strong></p><p style="text-align: center;"><strong></strong></p><p style="text-align: center;"><strong>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</strong></p><p style="text-align: center;"><strong></strong><strong>For the month of September 2025</strong></p><p style="text-align: center;">Commission File Number: <strong>001-39179</strong></p><p style="text-align: center;"><font style="font-size: 12pt;"><strong>Addex Therapeutics Ltd</strong></font><br />(Translation of registrant's name into English)</p><p style="text-align: center;"><strong>Chemin des Mines 9,<br /> CH-1202 Geneva,<br /> Switzerland<!--Chemin des Mines 9,<br> CH-1202 Geneva,--></strong><br />(Address of principal executive office)</p></div><p>Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.<br />Form 20-F [&#160;X ] &#160;&#160;&#160;&#160;&#160;Form 40-F [&#160;&#160; ]<br /><br /></p><hr style="page-break-after: always;" noshade="noshade" /><!--<p> <p>On September 23, 2025, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. <br /><br /><a href="exh_991.htm">(c) Exhibit 99.1. Press release dated September 23, 2025</a></p><p style="text-align: center;"><strong>INCORPORATION BY REFERENCE</strong></p><p style="text-align: left;">Exhibit 99.1 to this Report on Form 6-K shall be deemed to be incorporated by reference into the registration statement on Form F-3 (Registration No. 333-255089) of Addex Therapeutics Ltd and the registration statement on Form S-8 (Registration No. 333-255124 and No. 333-272515) of Addex Therapeutics Ltd (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.</p></p><p></p>--><p style="box-sizing: border-box; margin: 0px 0px 0.625em; color: #363636; font-family: 'Helvetica Neue', Helvetica, Arial, 'Lucida Grande', sans-serif; font-size: 14px;">&#160;<p>On September 23, 2025, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. <br /><br /><a href="exh_991.htm">(c) Exhibit 99.1. Press release dated September 23, 2025</a></p><p style="text-align: center;"><strong>INCORPORATION BY REFERENCE</strong></p><p style="text-align: left;">Exhibit 99.1 to this Report on Form 6-K shall be deemed to be incorporated by reference into the registration statement on Form F-3 (Registration No. 333-255089) of Addex Therapeutics Ltd and the registration statement on Form S-8 (Registration No. 333-255124 and No. 333-272515) of Addex Therapeutics Ltd (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.</p>&#160;</p><p style="box-sizing: border-box; margin: 0px 0px 0.625em; color: #363636; font-family: 'Helvetica Neue', Helvetica, Arial, 'Lucida Grande', sans-serif; font-size: 14px;" /><hr style="break-after: page;" noshade="noshade" /><p style="text-align: center;"><strong>SIGNATURE</strong></p><p>Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><table style="font-family: Times New Roman; font-size: 10pt;" border="0" width="100%" cellspacing="0" cellpadding="0"><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td style="text-decoration: underline;" align="center" width="47%"><strong>&#160;&#160;&#160;&#160;Addex Therapeutics Ltd&#160;&#160;&#160;&#160;</strong></td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td align="center" width="47%">(Registrant)</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td align="center" width="47%">&#160;</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td align="center" width="47%"></td></tr><tr valign="top"><td width="47%">Date: September 23, 2025</td><td width="6%">&#160;</td><td style="text-decoration: underline;" align="center" width="47%">&#160;&#160;&#160;&#160;/s/ Tim Dyer&#160;&#160;&#160;&#160;</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td align="center" width="47%">Tim Dyer</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td align="center" width="47%">Chief Executive Officer</td></tr><tr valign="top"><td width="47%">&#160;</td><td width="6%">&#160;</td><td align="center" width="47%"></td></tr></table><p><hr style="page-break-after: always;" noshade="noshade" /><p style="text-align: center;"><font style="font-size: 10pt;"><strong>EXHIBIT INDEX</strong></font></p><table style="font-size: 10pt;" border="0" cellspacing="0" cellpadding="0"><tr><td style="text-decoration: underline;" valign="bottom"><font style="font-size: 10pt;"><strong>Exhibit Number</strong></font></td><td width="20"><font style="font-size: 10pt;">&#160;</font></td><td style="text-decoration: underline;" valign="bottom"><font style="font-size: 10pt;"><strong>Description</strong></font></td></tr><tr><td>&#160;</td><td width="20"><font style="font-size: 10pt;">&#160;</font></td><td><font style="font-size: 10pt;">&#160;</font></td></tr><tr><td style="vertical-align: top;"><font style="font-size: 10pt;"><a href="exh_991.htm">99.1</a></font></td><td width="20"><font style="font-size: 10pt;">&#160;</font></td><td style="vertical-align: top;"><font style="font-size: 10pt;"><a href="exh_991.htm">Press release dated September 23, 2025</a> </font></td></tr></table></p></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exh_991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML lang="en-US"><HEAD><TITLE>EdgarFiling</TITLE>
<META content="text/html; charset=windows-1252" >
<META name="GENERATOR" content="MSHTML 8.00.7601.18094" ></HEAD>
<BODY>
<p ></p><p style="text-align: right;"><strong>EXHIBIT 99.1</strong></p><p style="text-align: center;"><strong>  Addex Appoints Bank of New York Mellon as Depositary Bank</strong></p><p style="text-align: center;" ></p><p>
 <p align="justify"><strong>Ad Hoc Announcement Pursuant to Art. 53 LR</strong></p>  <p align="justify"><strong>Geneva, Switzerland, September 23, 2025</strong> <strong>-</strong> Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced the appointment the Bank of New-York Mellon (BNY) as its new ADS depositary agent. This change is expected to become effective on October 6, 2025.&#160;</p>  <p align="justify">The appointment of BNY has no impact on the fees paid by ADS holders. At the effective date, no action will be required by the ADS holders.</p>  <p><strong>About Addex Therapeutics</strong></p>  <p align="justify">Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders. Addex&#8217;s lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is under evaluation for future development in brain injury recovery, including post-stroke and traumatic brain injury recovery. Addex&#8217;s partner, Indivior, has selected a GABAB PAM drug candidate for development in substance use disorders and has successfully completed IND enabling studies. Addex is advancing an independent GABAB PAM program for chronic cough. Addex also holds a 20% equity interest in a private spin out company, Neurosterix LLC, which is advancing a portfolio of allosteric modulator programs, including M4 PAM for schizophrenia, mGlu7 NAM for mood disorders and mGlu2 NAM for mild neurocognitive disorders. Addex shares are listed on the SIX Swiss Exchange and American Depositary Shares representing its shares are listed on the NASDAQ Capital Market, and trade under the ticker symbol &#8220;ADXN&#8221; on each exchange. For more information, visit www.addextherapeutics.com<br >&#160;&#160;<br ><strong>Contacts:&#160;</strong></p> <table style="border-collapse:collapse !important;;border-collapse: collapse; "><tr><td style="width:264px;;text-align: justify ;  vertical-align: middle; text-align: justify ;  vertical-align: middle; text-align: justify ;  vertical-align: middle; text-align: justify ;  vertical-align: middle; text-align: justify ;  vertical-align: middle; text-align: justify ;  vertical-align: middle; text-align: justify ;  vertical-align: middle; vertical-align: top ; ">     Tim Dyer&#160;<br >Chief Executive Officer&#160;<br >Telephone: +41 22 884 15 55&#160;<br >PR@addextherapeutics.com&#160;                                   </td><td style="width:237px;;text-align: justify ;  vertical-align: middle; text-align: justify ;  vertical-align: middle; text-align: justify ;  vertical-align: middle; text-align: justify ;  vertical-align: middle; text-align: justify ;  vertical-align: middle; text-align: justify ;  vertical-align: middle; text-align: justify ;  vertical-align: middle; vertical-align: top ; ">     Mike Sinclair&#160;<br >Partner, Halsin Partners&#160;<br >+44 (0)7968 022075&#160;<br >msinclair@halsin.com&#160;                                   </td></tr></table> <p align="justify"><strong>Addex Forward Looking Statements:</strong><br >This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements about the intended use of proceeds of the offering. The words &#8220;may,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;target&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in greater detail in the section entitled &#8220;Risk Factors&#8221; in Addex Therapeutics&#8217; Annual Report on Form 20-F, prospectus and other filings that Addex Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release represent Addex Therapeutics&#8217; views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking statements.</p> </p><p ></p>
</BODY></HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
